Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
AKBA
AKBA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AKBA News
Akebia Doses First Patient in Phase 2 Trial of Praliciguat for FSGS
Jan 07 2026
NASDAQ.COM
Akebia Doses First Patient in Phase 2 Trial of Praliciguat for FSGS
Jan 06 2026
Globenewswire
Akebia Grants 197,900 Stock Options to New Employee
Jan 05 2026
Globenewswire
What’s Driving the Surge in Small-Cap Q32 Bio Stock This Monday?
Dec 01 2025
Benzinga
Q32 Bio Sells ADX-097 for $12M, Extends Cash Runway into 2027
Dec 01 2025
PRnewswire
Akebia Acquires Q32 Bio's Next-Gen Kidney Disease Treatment
Dec 01 2025
Newsfilter
Akebia Reports GAAP EPS of $0.00, Exceeding Estimates by $0.01; Revenue of $58.78M Surpasses Expectations by $2.36M
Nov 10 2025
SeekingAlpha
Mettler-Toledo Exceeds Q3 Earnings Expectations Despite Year-over-Year Sales Drop
Nov 07 2025
NASDAQ.COM
Three Health Care Stocks That Could Revitalize Your Portfolio This November
Nov 04 2025
Benzinga
HC Wainwright & Co. Reaffirms Buy Rating for Akebia Therapeutics, Adjusts Price Target to $6
Oct 30 2025
Benzinga
FDA Resistance Leads Akebia to Abandon Efforts for Expansive Label on Kidney Disease Medication
Oct 29 2025
Benzinga
Major Stocks Including Mondelez International, Stride, and Varonis Systems Decline in Wednesday's Pre-Market Trading
Oct 29 2025
Benzinga
Teradyne Shares Surge Over 20%; Check Out 20 Stocks Making Moves in Premarket Trading
Oct 29 2025
Benzinga
Major Stock Movers on Wednesday: JOBY, ENPH, and Others
Oct 29 2025
SeekingAlpha
Akebia's Stock Drops After Decision to Discontinue Vafseo for Non-Dialysis Patients
Oct 28 2025
SeekingAlpha
Akebia Therapeutics to Showcase Five Presentations at ASN Kidney Week 2025
Oct 20 2025
Newsfilter
Show More News
